LONDON--(BUSINESS WIRE)--Technavio market research analysts forecast the global human leukocyte antigen (HLA) typing transplant market to grow at a CAGR of more than 9% during the forecast period, according to their latest report.
The market study covers the present scenario and growth prospects of the global HLA typing transplant market for 2017-2021. The report also lists systems and software as the two major product segments.
According to Srinivas Sashidar, a lead analyst at Technavio for in-vitro diagnostics research, “The increasing demand for organ transplantation has driven the sales of HLA typing tests. The growing incidence of chronic diseases such as kidney disease, end-stage renal disease, coronary artery disease, and acute and chronic hepatitis among all age groups has increased the need for HLA typing to reduce the graft rejection cases.”
Technavio’s insights help you make informed business decisions: Buy this report now
Technavio reports answer key questions relating to market size and growth, drivers and trends, top vendors, challenges, and more. Their analysts continuously monitor and evaluate the market landscape to help businesses assess their competitive position.
Technavio analysts highlight the following three market drivers that are contributing to the growth of the global HLA typing transplant market:
- Growing incidence of organ failure
- Technological advances in organ transplantation
- Acquisition of small hospitals by Tier 1 hospitals
Growing incidence of organ failure
The demand for tissue and organs such as bone marrow, heart, liver, kidney, and lungs is very high worldwide. The increasing rate of alcohol consumption, unhealthy lifestyles and food habits, and drug intake are the leading causes of organ failure. In addition, the rise in older adult population results in increased demand for organs for transplantation. According to a combined study conducted by the Department of Internal Medicine, Division of Hepatology, Loyola University Medical Center; Department of Preventive Health Sciences, Stritch School of Medicine, Loyola University Chicago; and Division of Gastroenterology and Hepatology, University of Michigan Health System, in 2015, liver cirrhosis is one of the major factors of death in the US.
As a part of the treatment, a person might undergo liver transplantation procedure. For liver recipients, HLA testing is conducted to match the HLAA, HLA B, and HLA DR LOCi. It is safe when the HLA of both organ donor and recipient matches as it reduces the graft rejection cases.
Technological advances in organ transplantation
The development of new and improved transplantation products, such as organ preservation solution for particular organs, tissue typing technology (HLA typing), and surgical medical instruments, drives the market growth. Also, the advances in PCR, such as improvements in system design and advanced assay development, provide high accuracy and efficiency in tissue typing. The advancement in transplant technology increases patient safety and monitors organ functioning. This ultimately increases the post-transplant recovery period.
Acquisition of small hospitals by Tier 1 hospitals
The growing acquisition of small hospitals has helped to increase organ transplantation, wound care, and transplant diagnosis in the market, which has indirectly impacted the growth of HLA typing transplant market positively. Tier 1 hospitals acquire small specialized hospitals, which helps to train the healthcare staff, physicians, and nurses. It also helps to meet growing patient needs by providing a range of patient monitoring equipment.
“The presence of skilled professionals in these hospitals encourages people to opt for these smaller specialty hospitals. The skills and techniques used by professional healthcare providers have improved with the increasing number of M&As. It helped the global HLA typing transplant market to grow,” says Srinivas.
Browse Related Reports:
- Global POC Lipid Testing Market 2017-2021
- Global Liquid Biopsy Market 2017-2021
- Global Influenza Diagnostics Market 2017-2021
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like oncology, vaccines, and urology devices. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
